DFTX · CIK 0001813814 · operating
Definium Therapeutics is a clinical-stage biopharmaceutical company developing treatments for brain health disorders. The company's pipeline centers on two primary candidates: MM120, currently in phase 3 trials for generalized anxiety disorder and attention deficit hyperactivity disorder, and DT402, a selective R-enantiomer formulation in phase 2a development for autism spectrum disorder symptom management. Both programs represent investigational approaches to neuropsychiatric conditions.
The company operates as a development-stage entity with no approved products generating revenue. As such, financial performance is driven by research and development spending, clinical trial costs, and capital financing rather than commercial operations. Definium was founded in 2019 and rebranded in January 2026 from its previous name, Mind Medicine (MindMed) Inc. The company maintains headquarters in New York and is incorporated in British Columbia, Canada, with operations primarily focused on clinical development activities.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-2.06 | $-2.06 | -33.8% | |
| 2024 | $-1.54 | $-1.54 | +36.9% | |
| 2023 | $-2.44 | $-2.44 | -32.6% | |
| 2022 | $-1.84 | $-1.84 | — | |
| 2021 | — | — | — |